Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas
Results demonstrate 77.8% overall response rate across dose levels with all complete responses at the highest dose level
Therapy well tolerated with no dose-limiting toxicities observed
SINGAPORE, Dec 13 (Bernama-GLOBE NEWSWIRE) —Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy being co-developed by Baylor College of Medicine and Tessa. The results demonstrated a favorable safety profile and encouraging signs of efficacy with clinical responses observed in seven out of nine patients, including a complete disappearance of tumor reported in four patients. The data was presented in an oral poster presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH).